Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide in metastatic hormone-sensitive prostate cancer
NCT02799602Phase 3Completed
- Sponsor
- Bayer
- Start
- Nov 2016
- Primary completion
- Oct 2021
- Modality
- Orthosteric Ligands
- Countries
- 23
01
Overview
A Phase 3 trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Started Nov 2016; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02799602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02799602.